Supportive Healthcare Policies and Funding Drive the Bladder Cancer Diagnosis and Treatment Market Growth

Bladder cancer diagnosis and treatment market was valued at $5,920 million in 2025 and is projected to reach $10,928 million by 2035, growing at a CAGR of 6.4% during the forecast period (2026–2035). Government and private initiatives to enhance cancer care infrastructure, reimbursement policies, and research and funding of breakthrough diagnostic technology are fundamental drivers of market growth. These activities benefit patient access to sophisticated treatments, speed the discovery and approval process of new therapy and diagnostic technologies.

Browse the full report description of “Bladder Cancer Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Product (Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Others) by Stage (Non-Muscle-Invasive (NMIBC) (Stage 0a, 0is, I.), and Muscle-Invasive (MIBC) (Stage II, III, IV (metastatic))  by Diagnosis (Cystoscopy, Biopsy, Urine Cytology, Intravenous Pyelogram, and Others), and By Treatment (Surgery, Chemotherapy, Immunotherapy, Radiation Therapy, and Others) Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/bladder-cancer-diagnosis-and-treatment-market

For instance, in June 2025, the FDA authorized mitomycin intravesical solution (Zusduri) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The study, the ENVISION trial, ascertained the efficacy of 75 mg mitomycin intravesical solution in treating low-grade NMIBC in 240 adults. Complete response (CR) at 3 months and duration of response (DOR) were the main outcomes. 78% of the patients had a CR, and 79% had sustained response for ? 12 months. Elevated creatinine, potassium, dysuria, low hemoglobin, and hematuria were frequent side effects. Serious adverse events occurred in 12% of patients.

Recent FDA Approvals and Developments Shaping Bladder Cancer Treatment:

• In July 2025, the FDA approved breakthrough device designation status for the TOBY Test, a urine-based test using an AI algorithm for the detection and monitoring of bladder cancer. The non-invasive, convenient, and less burdensome than cystoscopy is a significant milestone in the diagnosis of cancer.
• In July 2024, Johnson & Johnson gained FDA Priority Review for TAR-200, an intravesical gemcitabine-releasing system, to treat high-risk non-muscle invasive bladder cancer. The system, which delivers cancer treatment inside the bladder, has achieved an 82.4 percent complete response rate, with 52.9% of the patients still cancer-free after converting to a CR. The system is retained in the bladder for three weeks during each treatment cycle.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Stage
  • By Diagnosis
  • By Treatment
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Bladder Cancer Diagnosis and Treatment Market Report Segment

By Type

• Urothelial Carcinoma
• Squamous Cell Bladder Cancer
• Adenocarcinoma
• Others (Small Cell Carcinoma)

By Stage

• Non-Muscle-Invasive (NMIBC) (Stage 0a, 0is, I.)
• Muscle-Invasive (MIBC) (Stage II, III, IV (metastatic).

By Diagnosis

• Cystoscopy
• Biopsy
• Urine Cytology
• Intravenous Pyelogram
• Others

By Treatment

• Surgery
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Others (Intravesical therapies, Systemic chemotherapy, Targeted therapies & small molecules, and Antibody–drug conjugates (ADCs))

Global Bladder Cancer Diagnosis and Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bladder-cancer-diagnosis-and-treatment-market